CN1608621A - Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn - Google Patents
Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn Download PDFInfo
- Publication number
- CN1608621A CN1608621A CNA2003101018911A CN200310101891A CN1608621A CN 1608621 A CN1608621 A CN 1608621A CN A2003101018911 A CNA2003101018911 A CN A2003101018911A CN 200310101891 A CN200310101891 A CN 200310101891A CN 1608621 A CN1608621 A CN 1608621A
- Authority
- CN
- China
- Prior art keywords
- slow releasing
- releasing preparation
- medicine
- skeleton
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 125000002619 bicyclic group Chemical group 0.000 title claims abstract description 42
- 239000000843 powder Substances 0.000 title description 14
- 239000003814 drug Substances 0.000 claims abstract description 68
- 238000002360 preparation method Methods 0.000 claims abstract description 62
- 239000000463 material Substances 0.000 claims abstract description 12
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 claims description 35
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 16
- -1 hydroxypropyl Chemical group 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000007939 sustained release tablet Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 6
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 12
- 230000003111 delayed effect Effects 0.000 abstract description 8
- 208000002672 hepatitis B Diseases 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000008188 pellet Substances 0.000 abstract 2
- 238000002386 leaching Methods 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 30
- 229940079593 drug Drugs 0.000 description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 239000008101 lactose Substances 0.000 description 15
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 208000006454 hepatitis Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000009702 powder compression Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (16)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101018911A CN100542528C (en) | 2003-10-23 | 2003-10-23 | Bicyclol micronization and controlled release formulations for oral administration |
PCT/CN2004/001199 WO2005039561A1 (en) | 2003-10-23 | 2004-10-22 | Micronized bicyclol and the orally administered controlled release formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101018911A CN100542528C (en) | 2003-10-23 | 2003-10-23 | Bicyclol micronization and controlled release formulations for oral administration |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1608621A true CN1608621A (en) | 2005-04-27 |
CN100542528C CN100542528C (en) | 2009-09-23 |
Family
ID=34473851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101018911A Expired - Lifetime CN100542528C (en) | 2003-10-23 | 2003-10-23 | Bicyclol micronization and controlled release formulations for oral administration |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100542528C (en) |
WO (1) | WO2005039561A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006015546A1 (en) * | 2004-08-11 | 2006-02-16 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Use of bicyclol for manufacturing a medicament for preventing and/or treating acute alcoholism and acute or chronic alcoholic liver injury |
CN100444865C (en) * | 2006-07-06 | 2008-12-24 | 陈红亮 | Synergistic medicinal composition containing dicyclic alcohol |
EP2471521A1 (en) * | 2009-12-15 | 2012-07-04 | Beijing Union Pharmaceutical Factory | Double-layer osmotic pump controlled release tablet of bicyclol and preparation method thereof |
CN102058577B (en) * | 2008-08-06 | 2012-07-25 | 北京协和药厂 | Medicament compound adopting bicyclo-ethanol as active component and preparation thereof |
CN103230391A (en) * | 2013-01-24 | 2013-08-07 | 辽宁亿灵科创生物医药科技有限公司 | Bicyclol solid preparation |
CN103284953A (en) * | 2012-03-05 | 2013-09-11 | 辽宁亿灵科创生物医药科技有限公司 | Bicyclol solid preparation and preparation method thereof |
WO2013168179A2 (en) * | 2012-04-03 | 2013-11-14 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of antiviral agents |
CN105434356A (en) * | 2014-09-15 | 2016-03-30 | 北京协和药厂 | Bicyclol-encapsulating PLGA nanoparticle, and preparation method and uses thereof |
CN114533699A (en) * | 2021-12-15 | 2022-05-27 | 南通联亚药业股份有限公司 | Cyclobenzaprine hydrochloride sustained-release capsule and preparation method thereof |
CN114652692A (en) * | 2022-04-28 | 2022-06-24 | 长春钻智制药有限公司 | Medicine sustained-release tablet for treating liver diseases and preparation method and application thereof |
CN115844856A (en) * | 2023-01-06 | 2023-03-28 | 北京中科利华医药研究院有限公司 | Bicyclol solid preparation and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868207A (en) * | 1988-07-28 | 1989-09-19 | Taisho Pharmaceutical Co., Ltd. | Bis (methylenedioxy) biphenyl compounds useful for the treatment of liver diseases |
CN1049114C (en) * | 1995-12-07 | 2000-02-09 | 上海华联制药公司 | Method for prepn. of slowly-released medicaments preparation |
CN1212114C (en) * | 2001-04-27 | 2005-07-27 | 昆明制药集团股份有限公司 | oral breviscapine slow release preparation |
CN1476831A (en) * | 2003-07-18 | 2004-02-25 | 袁雪莲 | Biphenyl double-ester solid slowly-releasing composite |
-
2003
- 2003-10-23 CN CNB2003101018911A patent/CN100542528C/en not_active Expired - Lifetime
-
2004
- 2004-10-22 WO PCT/CN2004/001199 patent/WO2005039561A1/en active Application Filing
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006015546A1 (en) * | 2004-08-11 | 2006-02-16 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Use of bicyclol for manufacturing a medicament for preventing and/or treating acute alcoholism and acute or chronic alcoholic liver injury |
CN100444865C (en) * | 2006-07-06 | 2008-12-24 | 陈红亮 | Synergistic medicinal composition containing dicyclic alcohol |
CN102058577B (en) * | 2008-08-06 | 2012-07-25 | 北京协和药厂 | Medicament compound adopting bicyclo-ethanol as active component and preparation thereof |
EP2471521A1 (en) * | 2009-12-15 | 2012-07-04 | Beijing Union Pharmaceutical Factory | Double-layer osmotic pump controlled release tablet of bicyclol and preparation method thereof |
CN102091052B (en) * | 2009-12-15 | 2012-11-07 | 北京协和药厂 | Bicyclol double-layer osmotic pump control-released tablet and preparation method thereof |
EP2471521A4 (en) * | 2009-12-15 | 2013-07-10 | Beijing Union Pharmaceutical Factory | Double-layer osmotic pump controlled release tablet of bicyclol and preparation method thereof |
CN103284953B (en) * | 2012-03-05 | 2014-08-13 | 辽宁亿灵科创生物医药科技有限公司 | Bicyclol solid preparation and preparation method thereof |
CN103284953A (en) * | 2012-03-05 | 2013-09-11 | 辽宁亿灵科创生物医药科技有限公司 | Bicyclol solid preparation and preparation method thereof |
WO2013168179A2 (en) * | 2012-04-03 | 2013-11-14 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of antiviral agents |
WO2013168179A3 (en) * | 2012-04-03 | 2014-01-30 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of antiviral agents |
CN103230391A (en) * | 2013-01-24 | 2013-08-07 | 辽宁亿灵科创生物医药科技有限公司 | Bicyclol solid preparation |
CN105434356A (en) * | 2014-09-15 | 2016-03-30 | 北京协和药厂 | Bicyclol-encapsulating PLGA nanoparticle, and preparation method and uses thereof |
CN105434356B (en) * | 2014-09-15 | 2018-06-26 | 北京协和药厂 | A kind of PLGA nano particles of packet bicyclic alcohols and preparation method thereof, purposes |
CN114533699A (en) * | 2021-12-15 | 2022-05-27 | 南通联亚药业股份有限公司 | Cyclobenzaprine hydrochloride sustained-release capsule and preparation method thereof |
CN114652692A (en) * | 2022-04-28 | 2022-06-24 | 长春钻智制药有限公司 | Medicine sustained-release tablet for treating liver diseases and preparation method and application thereof |
CN114652692B (en) * | 2022-04-28 | 2023-09-01 | 长春钻智制药有限公司 | A sustained release tablet for treating liver diseases, and its preparation method and application |
WO2023208068A1 (en) * | 2022-04-28 | 2023-11-02 | 长春钻智制药有限公司 | Drug sustained-release tablet for treating liver disease, preparation method therefor and use thereof |
CN115844856A (en) * | 2023-01-06 | 2023-03-28 | 北京中科利华医药研究院有限公司 | Bicyclol solid preparation and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2005039561A1 (en) | 2005-05-06 |
CN100542528C (en) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100335046C (en) | Composition | |
CN1946426A (en) | Sustained release formulation for oral administration of HMG-CoA reductase inhibitor and method for the preparation thereof | |
CN101073563A (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
CN1608621A (en) | Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn | |
CN1237981C (en) | Ginkgoleaf oral cavity disintegrating tablet and its preparation method | |
CN1781485A (en) | Improved entecavir oral disintegrating tablet and its preparing method | |
CN1813860A (en) | Dispersible tablet for clearing away heat of brain and heart and preparation process thereof | |
CN1864679A (en) | A composite bergenin dispersible tablet and preparation method thereof | |
CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
CN1732953A (en) | Dispersible tablet for treating hypertension | |
CN101028329A (en) | Production and use for phyllanthin dispersing tablet preparation | |
CN1175818C (en) | Extractive preparation containing total alkali of mulberry leaves and its preparing method | |
CN1927185A (en) | Maleic acid trimebutine slow release tablet comprising quick release part and preparing method thereof | |
CN101036739A (en) | Chinese medicine preparation for treating stomach-ache and its preparation process | |
CN1887277A (en) | Dispersant tablet containing hypolipidemic component and its prepn process | |
CN1188131C (en) | Orally taken pulsed releasing system of phenyl diazepine medicine and its prepn. | |
CN1212840C (en) | Slow-releasing kurarinol preparation and its preparing method | |
CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
CN1895250A (en) | Gliquilone slow-releasing preparation | |
CN108785273B (en) | Entecavir capsule pharmaceutical composition and preparation method thereof | |
CN1899397A (en) | Heart activating oral disintergration tablet and its preparing method | |
CN1608620A (en) | Solid bicyclic alcohol dispersion | |
CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method | |
CN1593439A (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
CN1634014A (en) | Sodium ferulate oral disintegrating tablet and its preparation process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING UNION PHARMACEUTICAL FACTORY Free format text: FORMER OWNER: PHARMACOLOGY INST. OF CAMS Effective date: 20120618 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100050 XUANWU, BEIJING TO: 102600 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120618 Address after: 102600, Daxing District, Beijing Huang Town, Xingye Road, Beijing Concord pharmaceutical factory Patentee after: Beijing Union Pharmaceutical Factory Address before: 100050 Beijing city Xuanwu District Xiannongtan Street No. 1 Patentee before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 102600 building 7, 37 Yongwang Road, Daxing biomedical industrial base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: Beijing Xiehe Pharmaceutical Co.,Ltd. Address before: 102600 Beijing Xiehe pharmaceutical factory, Xingye North Road, Huangcun Town, Daxing District, Beijing Patentee before: Beijing Union Pharmaceutical Factory |
|
CX01 | Expiry of patent term |
Granted publication date: 20090923 |
|
CX01 | Expiry of patent term |